Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharmacosmos a.s. - ferric derisomaltose 417 mg/ml - eq. iron 100 mg/ml - solution for injection/infusion - 100 mg/ml - ferric derisomaltose 417 mg/ml - iron, parenteral preparations

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - ferric chloride - unknown - ferric chloride mineral-iron active 0.0 - active constituent

Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - ferric hydroxide sucrose compound - unknown - ferric hydroxide sucrose compound ungrouped active 0.0 - active constituent

Yhdysvallat - englanti - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly need

Yhdysvallat - englanti - NLM (National Library of Medicine)

actavis pharma, inc. - sodium ferric gluconate complex (unii: cc9149u2qx) (ferric cation - unii:91o4lml611) - ferric cation 12.5 mg in 1 ml - sodium ferric gluconate complex in sucrose injection is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. - known hypersensitivity to sodium ferric gluconate or any of its components. pregnancy category b there are no adequate and well-controlled studies with sodium ferric gluconate complex in sucrose injection in pregnant women. reproduction studies have been performed in mice at doses up to 100 mg/kg/day (300 mg/m2 /day) and in rats at up to 20 mg/kg/day (120 mg/m2 /day). the doses in mice and rats are 4 and 1.5 times the human dose of 125 mg/day (77 mg/m2 /day) on a body surface area basis and have revealed no evidence of harm to the fetus due to sodium ferric gluconate complex in sucrose injection. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly ne

Australia - englanti - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 4170 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 2085 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 834 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions:- when oral iron preparations are ineffective or cannot be used - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - ferric derisomaltose, quantity: 417 mg (equivalent: iron, qty mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - monofer is indicated for the treatment of iron deficiency in adults, under the following conditions: - when oral iron preparations are ineffective or cannot be used; - where there is a clinical need to deliver iron rapidly the diagnosis must be based on laboratory tests.